Design of a Genetically Modified Soybean Protein Preventing Hypertension Based on an Anti-Hypertensive Peptide Derived from Ovalbumin

Author(s): Nobuyuki Matoba, Yuko Yamada, Masaaki Yoshikawa.

Journal Name: Current Medicinal Chemistry - Cardiovascular & Hematological Agents

Volume 1 , Issue 2 , 2003

Abstract:

Food proteins can be a source of various bioactive peptides including such possessing anti-hypertensive activity. While most orally active anti-hypertensive peptides derived from food proteins inhibit the angiotensin Iconverting enzyme (ACE), ovokinin (2-7) (RADHPF), a peptide isolated from a chymotryptic digest of ovalbumin, has been shown to induce nitric oxide-dependent vasorelaxation in an isolated mesenteric artery as well as anti-hypertensive effect after oral administration in spontaneously hypertensive rats (SHRs). Rational amino acid replacement lead to the ovokinin (2-7) analog, RPLKPW, which had the highest anti-hypertensive activity among the tested peptides. Furthermore, oral administration (0.1 mg / kg) of the peptide lowered the blood pressure of SHR but not of normotensive Wistar-Kyoto (WKY) rats. In order to develop a novel use of this potent anti-hypertensive peptide for prevention of hypertension, RPLKPW has been genetically introduced into the homologous sequences in soybean β-conglycinin α subunit by site-directed mutagenesis. The recombinant RPLKPW-incorporated α subunit expressed in E. coli has been shown to exert anti-hypertensive activity after oral administration in SHR. Thus, RPLKPW-incorporated α subunit is the first example of a genetically modified food protein possessing physiological activity based on a bioactive peptide.

Keywords: ovalbumin, ovokinin, vasorelaxation, anti-hypertensive peptide, peptide design, soybean, genetically modified (gm) food, spontaneously hypertensive rat (shr)

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 1
ISSUE: 2
Year: 2003
Page: [197 - 202]
Pages: 6
DOI: 10.2174/1568016033477496
Price: $58

Article Metrics

PDF: 1